Skip to content

Asunaprevir

ANTIINFECTIVES FOR SYSTEMIC USE

Also known as: BMS-650032, sunvepra

PMDA approvedATC J05AP06ATC J05AP58

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Asunaprevir is a drug catalogued in DrugCentral. It was first approved by the PMDA in 2014. DrugCentral lists 4 molecular targets, including Genome polyprotein, pol and NS3. Recorded indications include Chronic hepatitis C.

  • Molecular targets: Genome polyprotein, pol, NS3 and NS3 (4 listed in DrugCentral).
  • Indications: Chronic hepatitis C.
  • ATC code: J05AP06 (Antivirals for treatment of HCV infections).
  • Molecular formula: C35H46ClN5O9S; molecular weight 748.29 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Chronic hepatitis C

Mechanism & targets

Molecular targets (4)

TargetGeneActionActivity
Genome polyprotein—inhibitorKi 9.40
IntegrasepolunknownIC50 9.00
NS3NS3unknownEC50 8.92
Genome polyproteinNS3unknownEC50 8.92

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2014-07-04PMDA——

ATC classification

ATC codeTherapeutic hierarchy
J05AP06ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HCV infections
J05AP58ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HCV infections

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Virologic failure306.2
Viral mutation identified283.8
Alanine aminotransferase increased133.0
Hepatocellular carcinoma130.9
Liver injury82.8
Hepatitis B reactivation80.0
Hepatic function abnormal79.9
Hepatitis B DNA increased65.1
Ascites61.6
Hepatic failure61.4
Renal impairment58.1
Pyrexia53.5

Chemical structure

Molecular formulaC35H46ClN5O9S
Molecular weight748.29 g/mol
CAS number630420-16-5
InChIKeyXRWSZZJLZRKHHD-WVWIJVSJSA-N
PubChem CID16076883
COC1=C2C=CC(Cl)=CC2=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)N=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Asunaprevir used for?

DrugCentral lists the following indications for Asunaprevir: Chronic hepatitis C.

How does Asunaprevir work?

Its molecular targets in DrugCentral include Genome polyprotein (inhibitor), pol, NS3 and NS3.

When was Asunaprevir first approved?

Asunaprevir was first approved by the PMDA in 2014.

What is the chemical formula of Asunaprevir?

Asunaprevir has the molecular formula C35H46ClN5O9S and a molecular weight of 748.29 g/mol.

Browse: all drugs starting with A · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

Status—
First approval2014-07-04
AgencyPMDA
Targets4
Indications1
FormulaC35H46ClN5O9S
DrugCentral ID4889
Interactive profile